When Sjögren syndrome presents with cutaneous annular erythema alongside evidence of active systemic disease, a structured, organ-specific treatment approach is required. The goal is to bring measurable systemic activity under control using established disease activity criteria.

Clinical Scenario

This protocol addresses patients with Sjögren syndrome who have cutaneous annular erythema and active systemic involvement. Treatment should be tailored to organ-specific severity using ESSDAI definitions, and may follow a sequential or combined therapeutic approach encompassing glucocorticoids, immunosuppressive agents, and biologics as appropriate.

First-Line Treatment Approach

For this presentation, the protocol specifies an antimalarial agent as the primary pharmacological intervention. The complete regimen — including full selection criteria, monitoring requirements, and escalation guidance — is available in the structured protocol.

Treatment target: ESSDAI score reduction of ≥3 points

References

DOI: 10.1136/annrheumdis-2019-216114

The systemic organ-specific therapeutic approach may follow, as a general rule, the sequential (or combined) use of GCs, immunosuppressive agents and biologics.
Treatment of systemic disease should be tailored to organ-specific severity using the ESSDAI definitions.
HCQ: hydroxychloroquine 200 mg/day.
With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of ≥3 points in the global ESSDAI score.

View source ↗

Treating Sjögren Syndrome with Cutaneous Annular Erythema and Active Systemic Disease

References